James Zhengwu Deng
Research Subjects
James Zhengwu Deng has a total of 148 co-authors. Here are the top co-authors by number of shared publications:
Ping Zhuang
Vaccine Analytical Research & Development, West Point, USA
4 shared publicationsChristopher S. Burgey
Department of Medicinal Chemistry, MRL, Merck & Co., Inc., PO Box 4, West Point, PA 19486, USA
3 shared publicationsJohn W. Loughney
Analytical Research and Development
3 shared publicationsRichard R. Rustandi
Analytical Research and Development
3 shared publicationsSha Ha
Vaccine Analytical Research & Development, West Point, USA
3 shared publicationsAndrew R. Swartz
Vaccine Process Research and Development, Merck & Co., Inc., Rahway, New Jersey, USA
2 shared publications
Latest Publications
- Open Access
- 12 September 2025
- Published by Wiley
Phage Display-Based Discovery of HPV Capsomere-Specific Antibodies for HPV Process Characterization
Human papillomaviruses (HPV) are a group of viruses that primarily infect squamous epithelial cells, often leading to proliferative lesions and various cancers. It is estimated that over 80% of sexually active adults will acquire HPV by the age of 45. The HPV capsid is composed of two major capsid proteins, L1 and L2, which co-assemble to form the viral structure. Notably, the L1 protein can self-assemble into virus-like particles (VLPs) that exhibit significant structural and immunological similarities to the native virus capsid. This self-assembly involves formation of critical repeating pentamer subunits known as capsomeres. In this study, we generated and characterized monoclonal antibodies (mAbs) specific to capsomeres to understand and improve HPV vaccine manufacturing process. We prepared high-purity Type16 capsomeres and utilized phage display technology to developed high affinity mAbs for T16 capsomeres. We used immunoassays and biophysical analyses to demonstrate that these antibodies can selectively bind to T16 capsomeres but not T16 VLPs. Furthermore, we established an enzyme-linked immunosorbent assay (ELISA) employing one of these antibodies to quantify capsomeres in cell lysates. Our findings demonstrate that these antibodies are valuable tools for probing process intermediates at previously inaccessible stages to enable greater process understanding and more efficient process development.
- 12 September 2025
- Published by Wiley
Open AccessPhage Display-Based Discovery of HPV Capsomere-Specific Antibodies for HPV Process Characterization
Human papillomaviruses (HPV) are a group of viruses that primarily infect squamous epithelial cells, often leading to proliferative lesions and various cancers. It is estimated that over 80% of sexually active adults will acquire HPV by the age of 45. The HPV capsid is composed of two major capsid proteins, L1 and L2, which co-assemble to form the viral structure. Notably, the L1 protein can self-assemble into virus-like particles (VLPs) that exhibit significant structural and immunological similarities to the native virus capsid. This self-assembly involves formation of critical repeating pentamer subunits known as capsomeres. In this study, we generated and characterized monoclonal antibodies (mAbs) specific to capsomeres to understand and improve HPV vaccine manufacturing process. We prepared high-purity Type16 capsomeres and utilized phage display technology to developed high affinity mAbs for T16 capsomeres. We used immunoassays and biophysical analyses to demonstrate that these antibodies can selectively bind to T16 capsomeres but not T16 VLPs. Furthermore, we established an enzyme-linked immunosorbent assay (ELISA) employing one of these antibodies to quantify capsomeres in cell lysates. Our findings demonstrate that these antibodies are valuable tools for probing process intermediates at previously inaccessible stages to enable greater process understanding and more efficient process development.
- 11 September 2025
- Published by American Chemical Society (ACS) in Analytical Chemistry
Investigating Interfacial Interactions between the Adjuvant and Antigens in Pneumococcal Conjugate Vaccine In Situ at the Molecular Level
Despite recent advances in prevention and treatment, pneumococcal disease is still a leading cause of serious illness and death among young children and elderly adults. Novel multivalent pneumococcal conjugate vaccines (PCVs) are under development against bacterial infections that cause pneumococcal disease. A PCV is a complex vaccine product consisting of polysaccharide antigens from multiserotypes. Each antigen is conjugated to a carrier protein, such as CRM197, to recruit long-lasting T-cell immune responses. In PCV, antigens are often formulated with an aluminum adjuvant to further enhance the efficacy of the vaccine. It is believed that antigen-aluminum adjuvant interactions play an important role in adjuvanticity and antigen potency, but detailed mechanisms have yet to be elucidated. In this research, a nonlinear optical spectroscopic technique, sum frequency generation (SFG) vibrational spectroscopy, was applied to study the interfacial conformations and orientations of the PCV antigen on the aluminum adjuvant surface, with the help of molecular dynamics simulations. Mechanisms of molecular interaction between the PCV antigens and the aluminum adjuvant are revealed in situ and in real time from the conformations and orientations acquired from SFG and simulations. The effects of the solution salt concentration and conjugation type on such interactions were studied. The findings obtained from this research provide design insights into the rational development of PCV formulations with improved performance.
- 11 September 2025
- Published by American Chemical Society (ACS) in Analytical Chemistry
Investigating Interfacial Interactions between the Adjuvant and Antigens in Pneumococcal Conjugate Vaccine In Situ at the Molecular Level
Despite recent advances in prevention and treatment, pneumococcal disease is still a leading cause of serious illness and death among young children and elderly adults. Novel multivalent pneumococcal conjugate vaccines (PCVs) are under development against bacterial infections that cause pneumococcal disease. A PCV is a complex vaccine product consisting of polysaccharide antigens from multiserotypes. Each antigen is conjugated to a carrier protein, such as CRM197, to recruit long-lasting T-cell immune responses. In PCV, antigens are often formulated with an aluminum adjuvant to further enhance the efficacy of the vaccine. It is believed that antigen-aluminum adjuvant interactions play an important role in adjuvanticity and antigen potency, but detailed mechanisms have yet to be elucidated. In this research, a nonlinear optical spectroscopic technique, sum frequency generation (SFG) vibrational spectroscopy, was applied to study the interfacial conformations and orientations of the PCV antigen on the aluminum adjuvant surface, with the help of molecular dynamics simulations. Mechanisms of molecular interaction between the PCV antigens and the aluminum adjuvant are revealed in situ and in real time from the conformations and orientations acquired from SFG and simulations. The effects of the solution salt concentration and conjugation type on such interactions were studied. The findings obtained from this research provide design insights into the rational development of PCV formulations with improved performance.
- 26 June 2025
- Published by Elsevier in Journal of Chromatography A
- Vol. 1758, 466174
Multi-attribute analysis of nanoparticle vaccine adjuvants by Electrical Asymmetrical Flow Field-flow Fractionation (EAF4) with light scattering detections
- 26 June 2025
- Published by Elsevier in Journal of Chromatography A
- Vol. 1758, 466174
Multi-attribute analysis of nanoparticle vaccine adjuvants by Electrical Asymmetrical Flow Field-flow Fractionation (EAF4) with light scattering detections
- Open Access
- 16 January 2025
- Published by SAGE Publications in Human Gene Therapy
- Vol. 36  (1-2) , 36-44
Interlaboratory Measurement of Adeno-Associated Virus: Comparative Quantification of Full and Empty Capsids
Recombinant adeno-associated virus (AAV) is one of the main viral vector-based gene therapy platforms. AAV is a virus consisting of a ≈25 nm diameter capsid with a ≈4.7 kb cargo capacity. Therapeutic safety and efficacy depend on the correct encapsidation of the DNA in individual virus particles, which is often characterized by the single scalar value of the ratio of full capsids with complete viral genomes to the total viral capsid number [the full-to-total (FTT) ratio]. This study reports on the interlaboratory and intertechnique variations of measurement methods for FTT among a cohort of organizations. The analytical methods used were sedimentation velocity analytical ultracentrifugation (SV-AUC) with UV/Vis and/or Rayleigh interference optics, size exclusion chromatography (SEC) with multi-angle light scattering (MALS), and tandem UV/Vis and/or refractive index, cryogenic electron microscopy, dual-wavelength ultraviolet spectrophotometry, and ELISA coupled with quantitative PCR (qPCR, dPCR, or ddPCR). FTT measurements for both AAV5 and AAV8 serotypes were similar, except for PCR–ELISA. The optical techniques (UV spectroscopy/SEC–MALS) showed <10% SD between laboratories, likely from the uniformity of existing industry protocols. AUC, while demonstrating good repeatability, had ≈25% SD interlaboratory, suggesting the need for standardized methods. PCR and ELISA had poor reproducibility due to variations in both PCR and ELISA protocols and instrumentation. The discussion presents intended future efforts to improve and harmonize these measurements to increase both the repeatability and reproducibility of AAV viral particle critical quality attributes such as FTT.
- 16 January 2025
- Published by SAGE Publications in Human Gene Therapy
- Vol. 36  (1-2) , 36-44
Open AccessInterlaboratory Measurement of Adeno-Associated Virus: Comparative Quantification of Full and Empty Capsids
Recombinant adeno-associated virus (AAV) is one of the main viral vector-based gene therapy platforms. AAV is a virus consisting of a ≈25 nm diameter capsid with a ≈4.7 kb cargo capacity. Therapeutic safety and efficacy depend on the correct encapsidation of the DNA in individual virus particles, which is often characterized by the single scalar value of the ratio of full capsids with complete viral genomes to the total viral capsid number [the full-to-total (FTT) ratio]. This study reports on the interlaboratory and intertechnique variations of measurement methods for FTT among a cohort of organizations. The analytical methods used were sedimentation velocity analytical ultracentrifugation (SV-AUC) with UV/Vis and/or Rayleigh interference optics, size exclusion chromatography (SEC) with multi-angle light scattering (MALS), and tandem UV/Vis and/or refractive index, cryogenic electron microscopy, dual-wavelength ultraviolet spectrophotometry, and ELISA coupled with quantitative PCR (qPCR, dPCR, or ddPCR). FTT measurements for both AAV5 and AAV8 serotypes were similar, except for PCR–ELISA. The optical techniques (UV spectroscopy/SEC–MALS) showed <10% SD between laboratories, likely from the uniformity of existing industry protocols. AUC, while demonstrating good repeatability, had ≈25% SD interlaboratory, suggesting the need for standardized methods. PCR and ELISA had poor reproducibility due to variations in both PCR and ELISA protocols and instrumentation. The discussion presents intended future efforts to improve and harmonize these measurements to increase both the repeatability and reproducibility of AAV viral particle critical quality attributes such as FTT.
- Open Access
Identification and Quantification of a Pneumococcal Cell Wall Polysaccharide by Antibody-Enhanced Chromatography Assay
Multivalent pneumococcal vaccines have been developed successfully to combat invasive pneumococcal diseases (IPD) and reduce the associated healthcare burden. These vaccines employ pneumococcal capsular polysaccharides (PnPs), either conjugated or unconjugated, as antigens to provide serotype-specific protection. Pneumococcal capsular polysaccharides used for vaccine often contain residual levels of cell wall polysaccharides (C-Ps), which can generate a non-serotype specific immune response and complicate the desired serotype-specific immunity. Therefore, the C-P level in a pneumococcal vaccine needs to be controlled in the vaccine process and the anti C-P responses need to be dialed out in clinical assays. Currently, two types of cell-wall polysaccharide structures have been identified: a mono-phosphocholine substituted cell-wall polysaccharide C-Ps1 and a di-phosphocholine substituted C-Ps2 structure. In our effort to develop a next-generation novel pneumococcal conjugate vaccine (PCV), we have generated a monoclonal antibody (mAb) specific to cell-wall polysaccharide C-Ps2 structure. An antibody-enhanced HPLC assay (AE-HPLC) has been established for serotype-specific quantification of pneumococcal polysaccharides in our lab. With the new anti C-Ps2 mAb, we herein extend the AE-HPLC assay to the quantification and identification of C-Ps2 species in pneumococcal polysaccharides used for vaccines.
Open AccessIdentification and Quantification of a Pneumococcal Cell Wall Polysaccharide by Antibody-Enhanced Chromatography Assay
Multivalent pneumococcal vaccines have been developed successfully to combat invasive pneumococcal diseases (IPD) and reduce the associated healthcare burden. These vaccines employ pneumococcal capsular polysaccharides (PnPs), either conjugated or unconjugated, as antigens to provide serotype-specific protection. Pneumococcal capsular polysaccharides used for vaccine often contain residual levels of cell wall polysaccharides (C-Ps), which can generate a non-serotype specific immune response and complicate the desired serotype-specific immunity. Therefore, the C-P level in a pneumococcal vaccine needs to be controlled in the vaccine process and the anti C-P responses need to be dialed out in clinical assays. Currently, two types of cell-wall polysaccharide structures have been identified: a mono-phosphocholine substituted cell-wall polysaccharide C-Ps1 and a di-phosphocholine substituted C-Ps2 structure. In our effort to develop a next-generation novel pneumococcal conjugate vaccine (PCV), we have generated a monoclonal antibody (mAb) specific to cell-wall polysaccharide C-Ps2 structure. An antibody-enhanced HPLC assay (AE-HPLC) has been established for serotype-specific quantification of pneumococcal polysaccharides in our lab. With the new anti C-Ps2 mAb, we herein extend the AE-HPLC assay to the quantification and identification of C-Ps2 species in pneumococcal polysaccharides used for vaccines.
- Open Access
- 4 July 2023
- Published by Springer Nature in Glycoconjugate Journal
- Vol. 40  (5) , 565-573
Characterization of pneumococcal serotype 7F in vaccine conjugation
Streptococcus pneumoniae is a highly invasive bacterial pathogen that can cause a range of illnesses. Pneumococcal capsular polysaccharides (CPS) are the main virulence factors that causes invasive pneumococcal disease (IPD). Pneumococcal CPS serotype 7F along with a few other serotypes is more invasive and likely to cause IPD. Therefore, 7F is a target for pneumococcal vaccine development, and is included in the two recently approved multi-valent pneumococcal conjugated vaccines, i.e. VAXNEUVANCE and PREVNAR 20.To support process and development of our 15-valent pneumococcal conjugated vaccine (PCV15), chromatographic methods have been developed for 7F polysaccharide and conjugate characterization. A size-exclusion chromatography (SEC) method with UV, light scattering and refractive index detections was employed for concentration, size and conformation analysis. A reversed-phase ultra-performance liquid chromatography (RP-UPLC) method was used for analysis of conjugate monosaccharide composition and degree of conjugation. The collective information obtained by these chromatographic analysis provided insights into the pneumococcal conjugate and conjugation process. Graphical Abstract
- 4 July 2023
- Published by Springer Nature in Glycoconjugate Journal
- Vol. 40  (5) , 565-573
Open AccessCharacterization of pneumococcal serotype 7F in vaccine conjugation
Streptococcus pneumoniae is a highly invasive bacterial pathogen that can cause a range of illnesses. Pneumococcal capsular polysaccharides (CPS) are the main virulence factors that causes invasive pneumococcal disease (IPD). Pneumococcal CPS serotype 7F along with a few other serotypes is more invasive and likely to cause IPD. Therefore, 7F is a target for pneumococcal vaccine development, and is included in the two recently approved multi-valent pneumococcal conjugated vaccines, i.e. VAXNEUVANCE and PREVNAR 20.To support process and development of our 15-valent pneumococcal conjugated vaccine (PCV15), chromatographic methods have been developed for 7F polysaccharide and conjugate characterization. A size-exclusion chromatography (SEC) method with UV, light scattering and refractive index detections was employed for concentration, size and conformation analysis. A reversed-phase ultra-performance liquid chromatography (RP-UPLC) method was used for analysis of conjugate monosaccharide composition and degree of conjugation. The collective information obtained by these chromatographic analysis provided insights into the pneumococcal conjugate and conjugation process. Graphical Abstract
- Open Access
- 23 January 2023
- Published by Springer Nature in npj Vaccines
- Vol. 8  (1) , 1-8
Antibody enhanced HPLC for serotype-specific quantitation of polysaccharides in pneumococcal conjugate vaccine
Bacterial infection remains as one of the major healthcare issues, despite significant scientific and medical progress in this field. Infection by Streptococcus Pneumoniae (S. Pneumoniae) can cause pneumonia and other serious infectious diseases, such as bacteremia, sinusitis and meningitis. The pneumococcal capsular polysaccharides (CPS) that constitute the outermost layer of the bacterial cell are the main immunogens and protect the pathogen from host defense mechanisms. Over 90 pneumococcal CPS serotypes have been identified, among which more than 30 can cause invasive pneumococcal diseases that could lead to morbidity and mortality. Multivalent pneumococcal vaccines have been developed to prevent diseases caused by S. Pneumoniae. These vaccines employ either purified pneumococcal CPSs or protein conjugates of these CPSs to generate antigen-specific immune responses for patient protection. Serotype-specific quantitation of these polysaccharides (Ps) antigen species are required for vaccine clinical dosage, product release and quality control. Herein, we have developed an antibody-enhanced high-performance liquid chromatography (HPLC) assay for serotype-specific quantitation of the polysaccharide contents in multivalent pneumococcal conjugate vaccines (PCVs). A fluorescence-labeled multiplex assay format has also been developed. This work laid the foundation for a serotype-specific antigen assay format that could play an important role for future vaccine research and development.
- 23 January 2023
- Published by Springer Nature in npj Vaccines
- Vol. 8  (1) , 1-8
Open AccessAntibody enhanced HPLC for serotype-specific quantitation of polysaccharides in pneumococcal conjugate vaccine
Bacterial infection remains as one of the major healthcare issues, despite significant scientific and medical progress in this field. Infection by Streptococcus Pneumoniae (S. Pneumoniae) can cause pneumonia and other serious infectious diseases, such as bacteremia, sinusitis and meningitis. The pneumococcal capsular polysaccharides (CPS) that constitute the outermost layer of the bacterial cell are the main immunogens and protect the pathogen from host defense mechanisms. Over 90 pneumococcal CPS serotypes have been identified, among which more than 30 can cause invasive pneumococcal diseases that could lead to morbidity and mortality. Multivalent pneumococcal vaccines have been developed to prevent diseases caused by S. Pneumoniae. These vaccines employ either purified pneumococcal CPSs or protein conjugates of these CPSs to generate antigen-specific immune responses for patient protection. Serotype-specific quantitation of these polysaccharides (Ps) antigen species are required for vaccine clinical dosage, product release and quality control. Herein, we have developed an antibody-enhanced high-performance liquid chromatography (HPLC) assay for serotype-specific quantitation of the polysaccharide contents in multivalent pneumococcal conjugate vaccines (PCVs). A fluorescence-labeled multiplex assay format has also been developed. This work laid the foundation for a serotype-specific antigen assay format that could play an important role for future vaccine research and development.
- Open Access
- 17 January 2023
- Published by SAGE Publications in Human Gene Therapy
- Vol. 34  (1-2) , 68-77
Quantitation of Coxsackievirus A21 Viral Proteins in Mixtures of Empty and Full Capsids Using Capillary Western
A prototype strain of Coxsackievirus A21 (CVA21) is being evaluated as an oncolytic virus immunotherapy. CVA21 preferentially lyses cells that upregulate the expression of intercellular adhesion molecule 1, which includes some types of tumor cells. CVA21 has an icosahedral capsid structure made up of 60 protein subunits encapsidating a viral RNA genome with a particle diameter size of 30 nm. Rapid and robust analytical methods to quantify CVA21 total, empty, and full virus particles are important to support the process development, meet regulatory requirements, and validate manufacturing processes. In this study, we demonstrate the detection of all four CVA21 capsid proteins, VP1, VP2, VP3, and VP4, as well as VP0, a surrogate for empty particles, using in-house-generated antibodies. An automated and quantitative capillary Western blot assay, Simple Western, was developed using these antibodies to quantify CVA21 total particles through VP1, empty particles through VP0, relative ratio of empty to full particles through VP0 and VP4, and the absolute ratio of empty to total particles through VP0 and VP1. Finally, this Simple Western method was used to support CVA21 cell culture and purification process optimization as a high-throughput analytical tool to make rapid process decisions.
- 17 January 2023
- Published by SAGE Publications in Human Gene Therapy
- Vol. 34  (1-2) , 68-77
Open AccessQuantitation of Coxsackievirus A21 Viral Proteins in Mixtures of Empty and Full Capsids Using Capillary Western
A prototype strain of Coxsackievirus A21 (CVA21) is being evaluated as an oncolytic virus immunotherapy. CVA21 preferentially lyses cells that upregulate the expression of intercellular adhesion molecule 1, which includes some types of tumor cells. CVA21 has an icosahedral capsid structure made up of 60 protein subunits encapsidating a viral RNA genome with a particle diameter size of 30 nm. Rapid and robust analytical methods to quantify CVA21 total, empty, and full virus particles are important to support the process development, meet regulatory requirements, and validate manufacturing processes. In this study, we demonstrate the detection of all four CVA21 capsid proteins, VP1, VP2, VP3, and VP4, as well as VP0, a surrogate for empty particles, using in-house-generated antibodies. An automated and quantitative capillary Western blot assay, Simple Western, was developed using these antibodies to quantify CVA21 total particles through VP1, empty particles through VP0, relative ratio of empty to full particles through VP0 and VP4, and the absolute ratio of empty to total particles through VP0 and VP1. Finally, this Simple Western method was used to support CVA21 cell culture and purification process optimization as a high-throughput analytical tool to make rapid process decisions.
- Open Access
- 1 January 2023
- Published by Elsevier in SSRN Electronic Journal
Chromatographic Characterization of Pneumococcal Serotype 7F in Vaccine Conjugation
Streptococcus pneumoniae is a highly invasive bacterial pathogen that can cause a range of illnesses. Pneumococcal capsular polysaccharides (CPS) are the main virulence factors that causes invasive pneumococcal disease (IPD). Pneumococcal CPS serotype 7F along with a few other serotypes is more invasive and likely to cause IPD. Therefore, 7F is a target for pneumococcal vaccine development, and is included in the two recently approved multi-valent pneumococcal conjugated vaccines, i.e. VAXNEUVANCE and PREVNAR 20. To support process and development of our 15-valent pneumococcal conjugated vaccine (PCV15), chromatographic methods have been developed for 7F polysaccharide and conjugate characterization. A size-exclusion chromatography (SEC) method with UV, light scattering and refractive index detections was employed for concentration, size and conformation analysis. A reversed-phase ultra-performance liquid chromatography (RP-UPLC) method was used for analysis of conjugate monosaccharide composition and degree of conjugation. The collective information obtained by these chromatographic analysis provided insights into the pneumococcal conjugate and conjugation process.
- 1 January 2023
- Published by Elsevier in SSRN Electronic Journal
Open AccessChromatographic Characterization of Pneumococcal Serotype 7F in Vaccine Conjugation
Streptococcus pneumoniae is a highly invasive bacterial pathogen that can cause a range of illnesses. Pneumococcal capsular polysaccharides (CPS) are the main virulence factors that causes invasive pneumococcal disease (IPD). Pneumococcal CPS serotype 7F along with a few other serotypes is more invasive and likely to cause IPD. Therefore, 7F is a target for pneumococcal vaccine development, and is included in the two recently approved multi-valent pneumococcal conjugated vaccines, i.e. VAXNEUVANCE and PREVNAR 20. To support process and development of our 15-valent pneumococcal conjugated vaccine (PCV15), chromatographic methods have been developed for 7F polysaccharide and conjugate characterization. A size-exclusion chromatography (SEC) method with UV, light scattering and refractive index detections was employed for concentration, size and conformation analysis. A reversed-phase ultra-performance liquid chromatography (RP-UPLC) method was used for analysis of conjugate monosaccharide composition and degree of conjugation. The collective information obtained by these chromatographic analysis provided insights into the pneumococcal conjugate and conjugation process.
- Open Access
Characterization of High Molecular Weight Pneumococcal Conjugate by SEC-MALS and AF4-MALS
Infections by Streptococcus pneumoniae can cause serious pneumococcal diseases and other medical complications among patients. Polysaccharide-based vaccines have been successfully developed as prophylactic agents against such deadly bacterial infections. In the 1980s, PNEUMOVAX® 23 were introduced as the first pneumococcal polysaccharide vaccines (PPSV). Later, pneumococcal polysaccharides were conjugated to a carrier protein to improve immune responses. Pneumococcal conjugate vaccines (PCV) such as PREVNAR® and VAXNEUVANCE™ have been developed. Of the more than 90 pneumococcal bacteria serotypes, serotype 1 (ST-1) and serotype 4 (ST-4) are the two main types that cause invasive pneumococcal diseases (IPD) that could lead to morbidity and mortality. Development of a novel multi-valent PCV against these serotypes requires extensive biophysical and biochemical characterizations of each monovalent conjugate (MVC) in the vaccine. To understand and characterize these high molecular weight (Mw) polysaccharide protein conjugates, we employed the multi-angle light scattering (MALS) technique coupled with size-exclusion chromatography (SEC) separation and asymmetrical flow field flow fractionation (AF4). MALS analysis of MVCs from the two orthogonal separation mechanisms helps shed light on the heterogeneity in conformation and aggregation states of each conjugate.
Open AccessCharacterization of High Molecular Weight Pneumococcal Conjugate by SEC-MALS and AF4-MALS
Infections by Streptococcus pneumoniae can cause serious pneumococcal diseases and other medical complications among patients. Polysaccharide-based vaccines have been successfully developed as prophylactic agents against such deadly bacterial infections. In the 1980s, PNEUMOVAX® 23 were introduced as the first pneumococcal polysaccharide vaccines (PPSV). Later, pneumococcal polysaccharides were conjugated to a carrier protein to improve immune responses. Pneumococcal conjugate vaccines (PCV) such as PREVNAR® and VAXNEUVANCE™ have been developed. Of the more than 90 pneumococcal bacteria serotypes, serotype 1 (ST-1) and serotype 4 (ST-4) are the two main types that cause invasive pneumococcal diseases (IPD) that could lead to morbidity and mortality. Development of a novel multi-valent PCV against these serotypes requires extensive biophysical and biochemical characterizations of each monovalent conjugate (MVC) in the vaccine. To understand and characterize these high molecular weight (Mw) polysaccharide protein conjugates, we employed the multi-angle light scattering (MALS) technique coupled with size-exclusion chromatography (SEC) separation and asymmetrical flow field flow fractionation (AF4). MALS analysis of MVCs from the two orthogonal separation mechanisms helps shed light on the heterogeneity in conformation and aggregation states of each conjugate.